MedTrace Logo

Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection

NCT05827328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-07-18

No results posted yet for this study

Summary

Exploring the optimal interval time in patients with the clinical diagnosis of lung cancer or mediastinal tumors indicated for thoracic surgeries after SARS-CoV-2 infection by comparing 30-day mortality and 30-day morbidity.

Conditions

  • Thoracic Diseases
  • Thoracic Surgery

Interventions

OTHER

Observation

Observe the 30-day mortality and 30-day morbidity.

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Peng Zhang · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-29
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827328 on ClinicalTrials.gov